Allogeneic transplantation for myelofibrosis: for whom, when, and what are the true benefits?

Item

http://www.wikidata.org/entity/Q38174781

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Allogeneic transplantation for ...... nd what are the true benefits?

@en

type

Item

label

Allogeneic transplantation for ...... nd what are the true benefits?

@en

prefLabel

Allogeneic transplantation for ...... nd what are the true benefits?

@en

P1476

Allogeneic transplantation for ...... nd what are the true benefits?

@en

P2093

Daria Babushok

http://www.w3.org/2001/XMLSchema#string

Elizabeth Hexner

http://www.w3.org/2001/XMLSchema#string

P2860

ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).

DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status.

Dynamic International Prognostic Scoring System scores, pre-transplant therapy and chronic graft-versus-host disease determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis.

Mature survival data for 176 patients younger than 60 years with primary myelofibrosis diagnosed between 1976 and 2005: evidence for survival gains in recent years.

Outcome of transplantation for myelofibrosis.

Allogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60-78 years of age.

IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F

The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation.

P304

114-122

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/MOH.0000000000000015

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24378706

http://www.w3.org/2001/XMLSchema#string

P932

4104209

http://www.w3.org/2001/XMLSchema#string